Tamsulosin 0.4 mg with Tadalafil 5 mg versus 2.5 mg to reduce symptoms from ureteral stents
Official title: Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg for Ureteric Stent Related Symptoms
Run by Ain Shams University · NCT07562282 · Data updated 2026-11-12
This will test whether adding Tadalafil at 5 mg or 2.5 mg to Tamsulosin 0.4 mg better reduces stent-related symptoms for adults with a double-J ureteral stent after stone removal.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 71 Years |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Cairo, Abbasia) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | July 1, 2026 |
| Study ends | July 10, 2026 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07562282 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 years old who have a polyurethane double-J stent placed after endoscopic kidney stone removal and who do not meet any exclusion criteria are appropriate candidates.
✕Probably not a fit
Patients with diabetes, renal dysfunction, solitary kidney, prior pelvic or lower urinary tract surgery, active cancer, significant cardiac or neurological disease, recent pelvic radiation, or those taking excluded medications are unlikely to be eligible or to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with polyurethane double-J stents placed after endoscopic stone removal receive Tamsulosin 0.4 mg plus either Tadalafil 5 mg or 2.5 mg and are followed for stent-related symptoms such as flank pain, urinary frequency, urgency, dysuria, hematuria, and sexual discomfort. The trial compares symptom burden and safety between the two tadalafil doses when used in combination with tamsulosin. Major exclusions include prior prostate or bladder surgery, significant cardiac disease, diabetes, kidney dysfunction, solitary kidney, neurological or oncologic conditions, recent pelvic radiation, or use of interacting medications. Outcomes focus on patient-reported symptom scores and adverse events during the stent dwell time.
Why it matters
Potential benefit: If successful, this combination could reduce stent-related symptoms and improve quality of life, possibly with fewer side effects or lower cost if the 2.5 mg dose proves effective.
How similar studies have gone: Previous studies suggest alpha-blockers and PDE5 inhibitors can reduce stent-related symptoms, but the combination of tamsulosin with a half-dose (2.5 mg) tadalafil has not been well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- patients older than 18 years of age, with presence of a double-J (DJ) stent (polyurethane) post endoscopic stone removal. Exclusion Criteria: * Patients younger than 18 years of age were excluded. * Patients with a history of prostate or bladder surgery were excluded. * Patients with prior lower urinary tract procedures were excluded. * Patients with cancer were excluded. * Patients with neurological conditions were excluded. * Patients with a history of pelvic radiation were excluded. * Patients with diabetes were excluded. * Patients with kidney dysfunction (acute or chronic) were excluded. * Patients with a solitary kidney were excluded. * Patients with congenital urinary anomalies were excluded. * Patients taking the following medications were excluded: * α-blockers * beta-blockers * calcium channel blockers * 5-alpha reductase inhibitors * PDE5 inhibitors * anticholinergics * nitrates * Patients with cardiac issues were excluded. * Patients with residual stone fragments after surgery were excluded. * Patients with multiple or bilateral ureteral stones were excluded. * Patients with long-term or bilateral stents requiring frequent changes were excluded. * Patients with interstitial cystitis were excluded. * Patients with chronic cystitis were excluded. * Patients with prostatitis were excluded. * Pregnant women were excluded. * Breastfeeding women were excluded. * Patients unavailable for follow-up were excluded.
Where it's running
-
Ain Shams University Hospital
Cairo, Abbasia, Egypt Recruiting
Study contacts
- Study coordinator: Ahmed Amr Mohammed Mounier, MSc
- Email: 160022@med.asu.edu.eg
- Phone: +201111984645
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emergency urinary drainage followed by PCNL in obstructive urosepsis
Doctors test whether the method of emergency drainage (retrograde ureteral stent or percutaneous nephrostomy) affects how well patients do after undergoing definitive PCNL.
-
Observation vs Upfront Surgery for Asymptomatic Kidney Stones in Children and Adults
This trial tests whether watching asymptomatic kidney stones or performing upfront surgery is better for reducing life disruption in patients aged 6 and older.
-
Two-Tier Virtual Reality Education to Reduce Anxiety Before Kidney Stone Surgery
This study tests whether a two-tier VR preoperative education approach can lower anxiety and improve knowledge and self-care in adults undergoing urolithiasis surgery.
-
Ureteral access sheath: omitting versus placing a stent after ureteroscopy
We will test if leaving out a ureteral stent after ureteroscopy with an access sheath works as well as placing a stent for pre-stented adults with kidney or ureteral stones.
-
Flexible versus semi-rigid ureteroscopy for upper ureteric stones under 2 cm
This will test whether flexible or semi-rigid ureteroscopy works better for adults with upper ureteric stones smaller than 2 cm.
-
Using a flexible suction sheath with flexible ureteroscopy for lower-pole kidney stones
This trial will test whether adding a flexible, navigable suction sheath to flexible ureteroscopy helps adults with lower-pole kidney stones become stone-free more often and avoid repeat procedures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.